LifeClean International (LCLEAN) Q4 2025 earnings summary

Executive summary

• Revenue for Q4 2025 was 10,195 TSEK, slightly down from 10,434 TSEK in Q4 2024; full-year revenue was 54,633 TSEK, down from 61,152 TSEK year-over-year.

• Adjusted EBITDA for Q4 was -6,505 TSEK (vs. -4,628 TSEK); full-year adjusted EBITDA was -21,041 TSEK (vs. -25,552 TSEK).

• Operating loss (EBIT) for Q4 was -9,930 TSEK (vs. -12,155 TSEK); full-year EBIT was -34,557 TSEK (vs. -50,186 TSEK).

• No dividend proposed for 2025.

Financial highlights

• Q4 cash flow from operations was -5,965 TSEK (vs. -8,359 TSEK); full-year cash flow from operations was -28,234 TSEK (vs. -40,826 TSEK).

• Q4 EBITDA improved to -8,345 TSEK from -9,701 TSEK; full-year EBITDA improved to -26,032 TSEK from -40,868 TSEK.

• Cash and cash equivalents at year-end were 6,876 TSEK (vs. 10,569 TSEK).

• Equity at year-end was 3,364 TSEK (vs. -3,631 TSEK).

Outlook and guidance

• Strategic review completed to maximize revenue potential; new go-to-market strategy and sales organization being established.

• Anticipates increased sales in Health segment as CE-marked products launch and biocides gain national registrations.

• Ongoing efforts to shorten sales cycles and build a sustainable sales pipeline.